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Abstract 
Mutations in the caveolin-3 gene (CAV3) can lead to a broad spectrum of clinical 
phenotypes. Phenotypes that have so far been associated with primary caveolin-3-
deficiency include limb girdle muscular dystrophy, rippling muscle disease, distal 
myopathy and hyperCKemia. This is the first report describing the clinical, 
pathological and genetic features of patients with caveolinopathy from the UK. Ten 
patients (six families) were identified via the National Commissioning Group (NCG) 
service for patients with limb girdle muscle dystrophy in Newcastle. Myalgia was the 
most prominent symptom in our cohort of patients and for 50% it was the reason for 
referral. Muscle weakness was only found in 60% of the patients, whereas rippling 
muscle movement was present in 80%. One of the patients reported episodes of 
myoglobinuria and another one episodes of hypoglycaemia. Five different mutations 
were identified, two of which were novel and three that had previously been 
described. Caveolinopathy needs to be considered as a differential diagnosis in a 
range of clinical situations, including in patients who do not have any weakness. 
Indeed, rippling muscles are a more frequent symptom than weakness, and can be 
detected in childhood. Presentation with myalgia is common and management of it as 
well as of myoglobinuria and hypoglycaemia may have a major impact on the 
patients’ quality of life. 
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Introduction  
Caveolae ('little caves'), are 50 to 100 nm small membrane invaginations on the 
surface of cells, which represent appendages or subcompartments of plasma 
membranes [1]. They participate in membrane trafficking, sorting, transport and signal 
transduction, including endocytosis and potocytosis. Caveolin is believed to play a 
role in the formation of the caveolae membranes, acting as a scaffolding protein that 
organizes and concentrates caveolin-interacting proteins and lipids in caveolae 
microdomains [2]. The mammalian caveolin gene family consists of three caveolins, 
caveolin-1, -2 and -3. Caveolins-1 and -2 are co expressed in adipocytes, whereas 
the expression of caveolin-3 is muscle specific [3].  
 
Caveolin-3 is a 21-24 kDa integral membrane protein formed of 151 amino acids 
(aa). Three separate segments can be identified in this protein, an N-terminal region 
(aa 1-73), a central hydrophobic transmembrane domain (aa 75-106) and a C-
terminal (aa 107-151) domain. The transmembrane domain is believed to form a 
hairpin loop structure in the cell membrane, allowing both the N- and C-terminal ends 
to face the cytoplasm. The N-terminal domain contains a caveolin signature 
sequence (aa 41-48, FEDVIAEP present in all caveolins) and a scaffolding domain 
(aa 55-74) known to bind various signalling proteins. It is also responsible for the 
homo-oligomerization and the interaction with caveolin-associated signalling 
molecules such as eNOS, β-adrenergic receptors, protein kinase C isoforms, G 
proteins, Src-family kinases, and multiple components of the dystrophin-glycoprotein 
complex [4, 5]. 
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Mutations in the CAV3 gene have been described in different domains of the 
protein. They are usually inherited in an autosomal dominant pattern and are 
associated with a broad spectrum of clinical phenotypes including LGMD1 C, distal 
myopathy, rippling muscle disease (RMD) and hyperCKaemia. Recently, an 
autosomal recessive inheritance of some CAV3 mutations was considered [6-9]. 
Different pathogenic mechanisms have been postulated to explain muscle 
pathology in caveolin-3 deficient muscles. First, it was found that mutated caveolin-3 
behaved in a dominant-negative fashion, causing the retention of wild type protein at 
the level of the Golgi apparatus [10]. Secondly, altered caveolin-3 expression 
changed the outcome of phosphoinositol-3-kinase activation from cell survival to cell 
death [11]. Thirdly, caveolin-3 null mice showed T-tubule abnormalities that could 
lead to dysregulation of muscular calcium homeostasis initiating a dystrophic process 
and possibly RMD [3]. 
 
Here we describe the clinical details of the first group of patients with 
caveolinopathy from the UK representing six families with five different mutations. Our 
cohort of patients showed various phenotypes that extend the clinical spectrum of 
patients with caveolin-3 deficiency. In addition, we found two novel mutations in the 
caveolin gene in our patients. 
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Patients and methods 
The Institute of Human Genetics in Newcastle Upon Tyne, UK serves as the 
national referral centre for patients with a possible diagnosis of limb girdle muscular 
dystrophy. The service is commissioned by the National Commissioning Group 
(NCG), covers residents from England, Wales and Scotland and provides clinical 
assessment, biopsy analysis and genetic testing. 
 
We describe 10 patients (3 male and 7 female) from six families with genetically 
confirmed mutations in the CAV3 gene. All patients underwent a thorough 
neurological assessment and six of them (one patient from each family) had a muscle 
biopsy. The manifestations of mechanical irritability of the muscles (percussion 
induced rapid contractions/PIRCs, mounding and rippling muscle movements) were 
assessed as previously described [12]. Serum creatine kinase levels were measured 
in all patients. Six patients had electrophysiological investigations. 
Muscle biopsy studies: Muscle biopsies were assessed by routine histochemistry 
and immunoanalysis. Optimised immunohistochemical and multiplex western blot 
protocols were used as previously described[13, 14]. 
Commercial antibodies to the laminin α5 chain (mAb 1924), laminin ß1 chain 
(mAb 1921), laminin γ1 chain (mAb 1920) and Collagen VI (mab 1944) were obtained 
from Chemicon International (Temecula, CA). Antibodies against α-dystroglycan 
(clone IIH6 )  was a gift from Kevin Campbell, β-spectrin (RBC2/3D5), β-dystroglycan 
(43DAG/8D5), C-terminal dystrophin (Dy8/6C5) and the N-terminal dystrophin  
(DY10/12B2), α-sarcoglycan  (Ad1/20A6), β-sarcoglycan (1/5B1), γ-sarcoglycan 
(35DAG/21B5), δ-sarcoglycan (3/12C1), neonatal Myosin (MHCn), laminin α2 chain 
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(NCL-Merosin) and dysferlin NCL-Hamlet /NCL-Hamlet were all from Novocastra. 
Caveolin-3 C38320 was supplied by Becton Dickinson. 
Briefly, sections were washed for 15 minutes in PBS pH 7.3 containing 0.1% 
Triton X to permeabilise the membranes. Excess buffer was removed and sections 
incubated overnight at 4°C in optimally diluted pri mary antibody diluted in 40% Foetal 
Calf Serum containing 0.1M lysine. Following 2x10 minute washes in PBS/Triton 
sections were incubated for 90 minutes at room temperature in HRP rabbit anti 
mouse IgG (Dako P260) diluted 1:100 in 0.1M lysine in 40% Foetal Calf Serum. 
Sections were washed for 2x10 minutes as above, visualised with 3,3'-
diaminobenzidene (DAB) and counterstained with Carazzi’s haematoxylin prior to 
dehydration and mounting. Control sections were labelled without primary antibodies, 
and all sections were compared with control samples from other neuromuscular 
disorders, and with normal muscle.  
Multiplex Western blot analysis was performed using biphasic polyacrylamide 
gradient gels 4-12% gels and antibodies against dysferlin (NCL-hamlet), calpain 3 
(Calp3d/2C4 and Calp3c/12A2), dystrophin (Dy8/6C5 C-terminus and Dy4/6D3 rod 
domain), α-sarcoglycan (Ad1/20A6), β-dystroglycan ( 43DAG/8D5), γ-sarcoglycan 
(35DAG/21B5), the laminin α2 chain (Chemicon MAB 1922) and Caveolin-3 C38320. 
Myosin heavy chain staining on the post blotted gel was used to indicate how much 
actual muscle protein (as opposed to fat and fibrous connective tissue) was loaded in 
each lane[13]. 
Mutation analysis. 
Genomic DNA (50–100 ng) extracted from peripheral blood lymphocytes was used as 
a template for PCR amplification. Reactions with exon-specific primers were 
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performed as previously described [6]. Thirty-five cycles of amplifications were 
performed as described above with an annealing temperature of 55°C[6]. PCR 
products were digested with BclI (LifeTechnologies, Karlsruhe, Germany) and 
products were analyzed by electrophoresis on a 2% Seakem LE agarose (FMC, 
Rockland, ME) gel stained with ethidium bromide.  
Bi-directional fluorescent sequencing was performed using dye terminator cycle 
sequencing chemistry and analysed on either 373A Fluorescent Automated 
Sequencer (Applied Biosystems) or a CEQ8000 Genetic Analysis System (Beckman 
Coulter). 
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Results 
Clinical history and examination 
In our current study, we analyzed the clinical history, clinical presentation and 
other diagnostic findings of 10 patients with mutations in their CAV3 gene. Table 1 
summarizes the clinical findings in our patients. 
The mean age at onset of symptoms was 14 years (range 5 - 32 years). The first 
disease related complaints (presenting symptoms) included myalgia, toe walking, 
muscle weakness and rippling muscle movements. Muscle pain was the presenting 
symptom in five patients. Pain was associated with cramps (spontaneous or post 
exertion) and was described as a dull aching pain. Severity of pain ranged from mild 
muscle discomfort to almost unbearable pain. Pain in one patient (patient 8) was so 
severe that it was insufficiently controlled with 450 mg tramadol hydrochloride plus 4 
g paracetamol per day. Other presenting symptoms included toe walking, rippling 
muscle movements, and large chunky calves. None of the patients presented with 
respiratory or cardiac symptoms. 
One patient (patient 4) reported several episodes of myoglobinuria (acute muscle 
cramps, myalgia and pigmenturia triggered by exercise) at around 20 year of age. 
Interestingly this patient did not show evidence of weakness at the time of 
examination. To our knowledge, this is the first time myoglobinuria has been reported 
in a patient with caveolinopathy. Another patient (patient 3) described multiple 
hypoglycaemic episodes for many years. On sustained aerobic exercise, she 
developed symptoms of dizziness and became sweaty. These symptoms also 
occurred after occasional fasting periods. They were aborted by eating something 
containing sugar. Her blood glucose level reached 3.0 mmol during one of these 
episodes. She reported that her half brother (who has identical muscle symptoms) 
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also has similar episodes. Chronic (cyclic) neutropenia was reported in another 
patient. Her neutrophil count has been as low as 2.3× 109. Despite extensive 
haematological investigations no definite cause for her neutropenia was identified and 
it remains unclear if this related to the caveolinopathy. 
The duration of the disease at diagnosis varied between 3 to 41 years. All 
patients had noticed muscle hypertrophy especially in the calf muscles during the 
course of their disease. One patient presented with bilateral wasting of small hand 
muscles. Eight patients reported rippling movements in their muscles. Rippling was 
induced by applying pressure to a stretched muscle. Most patients knew how to 
induce rippling. Mounding was present in two of those patients. Most of the patients 
who showed rippling movements did also show percussion induced rapid contractions 
(PIRCs, [12]), which were easily elicited in both muscles of the upper and lower limbs. 
Proximal weakness affecting both the upper and lower limbs was found in six 
patients. The weakness was bilateral and symmetrical. Its degree varied from MRC 
grade 4 in the shoulder girdle and grade 3-4 in the pelvic girdle muscles. Two patients 
showed associated MRC grade 4 weakness of the interossei muscles and one of 
them had associated weakness of the thumb muscles. In the three patients 
presenting with toe walking there was no evidence of distal weakness in the lower 
legs. Interestingly four of our patients showed no muscle weakness at all after a 
disease history of 13-31 years. Two of these patients showed mild finger flexion 
contractures and tight hamstrings. There were no signs of facial weakness, scapular 
winging or spinal rigidity in our patients. 
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Family history 
Family history analysis helped to identify the autosomal dominant pattern of 
inheritance in three families and allowed identification of other affected family 
members. Intrafamilial phenotypic variability was seen in two families. In one of the 
families, a mildly affected mother without rippling muscle disease had four affected 
children with rippling muscle disease. In another family the affected mother (patient 5) 
presented with weakness without evidence of rippling movements, whereas her 
affected children presented with rippling movements without evidence of weakness 
(patient 6) and with toe walking (patient 7). Patient four reported that his mother, 
sister, son and daughter all showed toe walking and calf hypertrophy, suggestive of 
caveolinopathy. 
 
Diagnostic investigations (electrophysiology, CK) 
The results of the electrophysiological assessments, CK values and muscle 
biopsies are presented in table 2. Serum CK levels were elevated in all patients. CK 
levels were elevated three to thirty fold. In eight patients, CK levels were nine fold 
above normal. EMG was done in six patients. All patients showed myopathic 
changes. Two patients showed spontaneous fibrillation potentials and positive sharp 
waves at rest.  
 
Muscle morphology and immunoanalysis: 
Index cases in each family underwent a muscle biopsy. The histopathological 
features of the muscle varied from dystrophic appearance (variation in fibre size, fibre 
splitting, internal nuclei, fibre necrosis and regeneration) to biopsies without any 
abnormalities. In patient 5 H&E staining showed rimmed vacuoles in addition to other 
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dystrophic changes. Interestingly this patient showed evidence of distal weakness 
and wasting. None of the biopsies was reported to show excess glycogen storage on 
Periodic acid-Schiff (PAS) staining. The immunoanalysis of skeletal muscle sections 
showed absent to weak caveolin staining (figure 1). This was associated with 
secondary reduction in dysferlin staining in two biopsies. Dysferlin staining was within 
normal range in the rest of the biopsies. Immunoblotting showed absent caveolin in 
three patients. Immunoblotting of the other proteins used in the panel, including 
dysferlin, was normal (figure 1). 
 
Results of CAV3 gene analysis: 
In our group of patients, we found two novel missense mutations in the CAV3 
gene in two unrelated families. The sequence variants were not found in control 
samples. The first mutation is 141 G/T in exon 2 leading to the substitution of 
glutamine by aspartate at position 47 of the caveolin signature domain. This mutation 
was found in two sisters. The second mutation is 218 A/G in exon 2 leading to the 
substitution of tryptophan by cysteine at position 73 of the scaffolding domain of the 
protein. This mutation was found in one patient. The mutation in the first patient (301 
T/C leading to the substitution of tryptophan by arginin in position 101 of the 
transmembrane domain of the caveolin-3 protein) has previously been reported [15]. 
The substitution of 80 G>A in exon 1 causing an amino acid change of arginin to 
glutamine in position 27 in the N-terminal domain of caveolin was reported in one 
family and it was described before in a patient with reduced caveolin-3 expression 
and rippling muscle disease [16]. The substitution of 136G>A in exon 2 causing an 
amino acid change of alanine to threonine in position 46 in the caveolin-signature 
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domain was identified in two families (patients 5, 6, 7 and patient 10). This mutation 
has been described before [17, 18]. 
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Discussion  
Mutations in the CAV3 gene can cause a wide spectrum of clinical phenotypes 
including hyperCKaemia, rippling muscle disease, distal myopathy and limb girdle 
muscular dystrophy (LGMD1C) [19]. Many patients show an overlap of these 
symptoms and it has therefore been suggested to use the term caveolinopathy for 
patients with a primary caveolin defect. 
In our cohort of patients, muscle pain was one of the main presenting symptoms 
and had a bigger impact on quality of life than muscle weakness. Caveolinopathy 
should always be included in the differential diagnosis of myalgia as it can be the only 
clinical symptom of a CAV3 mutation. The presence of muscle pain in 
caveolinopathies may be explained by impaired glucose metabolism in muscle and a 
shift to anaerobic glycolysis. It has recently been reported that in the absence of 
caveolin-3 phosphofructokinase (PFK), a key regulatory enzyme in the glycolytic 
pathway, is no longer targeted to the plasma membrane and is excluded from 
caveolar membrane domains [20, 21]. Patients with phosphofructokinase-deficiency 
(Glycogenosis type VII) do also frequently experience myalgia. The mislocalisation of 
phosphofructokinase in caveolinopathy could lead to an impaired glucose metabolism 
and might explain some of the clinical symptoms associated with the disease [21]. 
The biopsies of our cohort of patients showed no abnormalities on PAS-staining. PFK 
analysis was not performed on the patients’ biopsies. Interestingly one of our patients 
experienced episodes of myoglobinuria, which to our knowledge has not been 
reported before in caveolinopathy. The postulated phosphofructokinase 
mislocalisation may also play a role in the pathogenesis of this symptom as 
myoglobinuria is a common feature in patients with phosphofructokinase deficiency. 
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Myoglobinuria and its sequelae should therefore be discussed with patients with 
caveolinopathy.  
Another one of our patients developed well documented episodes of 
hypoglycaemia and so did a family member who had identical muscle symptoms. 
This observation suggests that these hypoglycaemic episodes could be related to the 
caveolinopathy. This would also be in accordance with recent reports on caveolin-3 
deficient mice, which showed that caveolin-3 null mice develop insulin resistance [22, 
23]. Proper assessment of glucose homeostasis in patients will be necessary to 
better characterize abnormalities of glucose metabolism in caveolin-3-deficiency. 
 
The presence and distribution of muscle weakness in our patients was variable. 
Forty percent of the patients showed no signs of muscle weakness as a manifestation 
of their disease. In the remaining patients, weakness was affecting limb girdle 
muscles. Two of the patients showed associated distal weakness in the interossei 
and thumb muscles. We found that there was no correlation between the 
development of weakness and the duration of the disease. Some patients developed 
weakness within 2 years of onset and other not even after 30 years.  
 
Manifestations of muscle hyperirritability (Rippling muscle movements and PIRCs) 
were found in eight patients. Neither PIRCs nor rippling was necessarily seen as a 
clinical problem by the patients. Both PIRCs and rippling movements were highly 
suggestive of CAV 3 gene abnormalities in the patients. On the other hand there are 
patients with rippling muscle movements without mutations in CAV3 gene [24]. With 
regard to recent reports on immune-mediated RMD it is important to remember that 
other diseases like myasthenia gravis can be associated with secondary caveolin-3 
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deficiency. Clinically it may be difficult to distinguish between primary caveolin-3 
deficiency and idiopathic RMD. HyperCKaemia is a well known presentation of 
mutations in the CAV3 gene. Recently it has even been described in caveolinopathy 
cases with normal caveolin expression in the muscle [25]. CK elevation can be mild 
and does correlate neither with the affected caveolin domain nor with disease 
duration. 
 
Muscle biopsy analysis can be helpful in the diagnosis of caveolinopathy. 
Reduction or complete loss of caveolin-3 expression was found in 4 biopsies. On the 
other hand secondary loss of caveolin-3 expression can be seen in other muscle 
diseases such as LGMD2B [26]. In several patients with caveolin-3-deficiency we 
excluded a primary CAV3 mutation, but have not been able to identify the underlying 
cause for the disease. In a recent report, two cases with hyperCKaemia and proven 
CAV3 mutations showed normal caveolin expression in their muscles [25]. The broad 
spectrum of clinical phenotypes associated with the same mutation in our cohort of 
patients confirms the previously mentioned phenotypic variability in caveolinopathy. 
 
In conclusion, this is the first report of a cohort of patients with caveolinopathy in 
the UK. The phenotypic spectrum seen in caveolinopathy included muscle pain, 
absence of weakness and myoglobinuria. The differential diagnosis for these 
symptoms is broad and includes metabolic myopathies, Becker muscular dystrophy 
and patients with FKRP mutations [27]. Other non-muscle related symptoms such as 
hypoglycaemia may also be associated with caveolin-3 deficiency. The presence of 
PIRCs and rippling movements does not seem to impact on the quality of life of 
patients but is a useful symptom to diagnose caveol
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Figure and table legends 
Figure 1: Skeletal muscle sections from control muscle (a), patient 1 (b), patient 2 (c) 
and patient 10 (d) were stained with caveolin-3 antibodies. Caveolin-3 expression 
was either severely reduced (b) or completely lost (c, d). Magnification 20x for (b) 
and 10x for (a, c and d). No caveolin-3 band was detectable on the Western blot of 
patient 1(e). The bands for the other proteins were normal compared to control. 
 
a) b) 
c) d) e) 
control Patient 1 
Dystrophin 
427 KD 
 
 
 
 
 
 
 
 
Calpain 3 
94 KD 
 
 
 
-Dystroglycan 
43 KD 
 
Calpain 3 
fragment 30 KD 
 
Caveolin-3 
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Table 1: The table summarizes the clinical data of the 10 patients.  
Number Sex 
Age 
at 
onset 
Presenting 
symptoms 
Age at 
assessment  Rippling PIRCs Weakness 
Muscle 
state Pain 
1 M 5-6 years 
tip toe 
walking 8 years yes yes 
proximal 
upper & 
lower 
limbs  
mild 
hypertrophy no 
2 F 6-7 years 
pain & 
rippling 22 years yes yes no 
generalised 
hypertrophy yes 
3 F 15 years 
cramps & 
rippling 28 years yes yes no 
mild 
hypertrophy yes 
4 M 6-7 years 
tip toe 
walking & 
large 
calves 
38 years yes yes no mild hypertrophy yes 
5 F 15 years weakness 56 years no no 
proximal & 
distal 
upper & 
lower 
limbs 
mild 
hypertrophy 
of calves & 
wasting of 
hand 
muscles 
no 
6 M 7-8 years rippling 25 years yes yes no 
mild 
hypertrophy no 
7 F 7-8 years 
tip toe 
walking & 
waddling 
gait 
23 years yes yes 
proximal 
upper & 
lower 
limbs 
mild 
hypertrophy no 
8 F 30 years pain 34 years yes no 
proximal 
upper & 
lower 
limbs 
hypertrophy yes 
9 F 32 years pain 36 years  yes yes 
proximal & 
distal 
upper & 
lower 
limbs 
hypertrophy yes 
10 F 13 years 
pain on 
exercise 15 years no yes 
 proximal 
upper 
&lower 
limbs 
mild 
hypertrophy yes 
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Table 2: The table summarizes the results of additional investigations in the 10 
patients. AB, antibody; Ck, creatine kinase; EMG, electromyography; * refers to 
newly described mutations. 
Biopsy 
Immunohistochemistry WB Patient CK (age) EMG Histology 
Caveolin-3 other AB Caveolin-3 
Mutation 
1 1340 (8y) 
myopathic 
features normal absent 
no 
abnormalities absent 
Ex2:301T/C 
Trp101Arg* 
2 5000 (22) 
myopathic 
features, 
sponteneous 
activities at 
rest 
mild fibre size 
variation 
markedly 
reduced 
weak 
dysferlin 
expression 
absent Ex1:80G/A Arg27Gln 
3 1070 (28) not done not done not done not done not done 
Ex1:80G/A 
Arg27Gln 
4 1754 (38)  
chronic 
myopathy 
dystrophic 
features not done 
no 
abnormalities not done 
Ex2:218A/G 
Tyr73Cys* 
5 2316 (56) not done 
dystrophic 
features and 
rimmed 
vacuoles 
not done not done not done Ex2:136G/A Ala46Thr 
6 2782 (25) not done not done not done not done not done 
Ex2:136G/A 
Ala46Thr 
7 1400 (23) 
myopathic 
features not done not done not done not done 
Ex2:136G/A 
Ala46Thr 
8 1856 (35) 
mild 
myopathic, 
sponteneous 
activities 
myopathic 
changes absent 
weak and 
patchy beta-
spectrin 
expression 
absent Ex2:141G/T Glu47Asp* 
9 662 (32) myopathic features  not done not done not done not done 
Ex2:141G/T 
Glu47Asp* 
10 887 (15) not done dystrophic features absent 
reduced and 
patchy 
laminin beta1 
& dysferlin 
expression 
not done Ex2:136G/A Ala46Thr 
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